Epidemiology and Burden of Disease

  • Mark W. RussoEmail author


Autoimmune hepatitis is an uncommon chronic liver disease that affects women more frequently than men. This chapter will focus on epidemiology of AIH describing differences in incidence and prevalence among countries and regions, differences by gender, race, and ethnicity, as well as burden of disease. The highest incidence and prevalence of AIH are seen in Scandinavian countries and native Alaskans. Blacks and Latinos present with more severe disease and advanced fibrosis. The economic burden and hospitalizations are also described.


Prevalence Incidence Rate 



autoimmune hepatitis


antibodies to liver kidney microsome type 1


antibodies to soluble liver antigen


  1. 1.
    Francque S, Vonghia L, Ramon A, Michelsen P. Epidemiology and treatment of autoimmune hepatitis. Hepat Med: Evid Res. 2012;4:1–10.Google Scholar
  2. 2.
    Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33:99–103.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Gronbaek L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014;60:612–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska natives. Am J Gastroenterol. 2002;97:2402–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Czaja AJ. Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol. 2011;25:689–700.CrossRefGoogle Scholar
  6. 6.
    Primo J, Merino C, Fernandez J, et al. Incidence and prevalence of autoimmune hepatitis in the area of the Hospital de Sagunto (Spain). Gastroenterol Hepatol. 2004;27:239–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Enomoto H, Nishiguchi S. Similarities and differences in autoimmune hepatitis epidemiology between East and West: autoimmune hepatitis in East Asia, Southeast Asia and South Asia. Inflamm Intest Dis. 2016;1:150–8.CrossRefGoogle Scholar
  8. 8.
    Lee YM, Teo EK, Ng TM, Khor C, Fock KM. Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women. J Gastroenterol Hepatol. 2001;16:1384–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Kim BH, Choi HY, Ki M, et al. Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea. PLoS One. 2017;12(8):e0182391.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol. 2008;43:1232–40.PubMedCrossRefGoogle Scholar
  11. 11.
    Lv TT, Li M, Zeng N, Zhang J, Li S, Chen S, et al. A systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European and American population. J Gastroenterol Hepatol. 2019; Scholar
  12. 12.
    Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259–60.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Delgado JS, Vodonos A, Malnick S, et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study. J Dig Dis. 2013;14:611–8.PubMedGoogle Scholar
  14. 14.
    Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55:2144–61.PubMedCrossRefGoogle Scholar
  15. 15.
    Al-Chalabi T, Underhill JA, Portmann BC, et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol. 2008;48:140–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Young NA, Wu LC, Burd CJ, et al. Estrogen modulation of endosome-associated toll-like receptor 8: an IFN alpha-independent mechanism of sex-bias in systemic lupus erythematosus. Clin Immunol. 2014;151:66–77.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013;339:1084–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol. 2002;97:2051–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007;46:1828–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinco-laboratory and histological characteristics. World J Gastroenterol. 2015;21:60–83.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol. 2001;96(12):3390–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol. 2012;46:155–61.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337:1183–7.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Chen J, Eslick GD, Welman M. Systematic review and meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment Pharmacol Ther. 2014;39:117–24.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Al-Chaibabi T, Boccato S, Portmann BC, et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006;45:575–83.CrossRefGoogle Scholar
  26. 26.
    Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type I autoimmune hepatitis in the elderly. Hepatology. 2006;43:532–8.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology. 1999;30:1374–80.PubMedCrossRefGoogle Scholar
  28. 28.
    Coulo CA, Bittencourt PL, Porta G, et al. Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity in autoimmune hepatitis. Hepatology. 2014;59:592–600.CrossRefGoogle Scholar
  29. 29.
    Mehendiratta V, Mitroo P, Bombonati A, et al. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2009;7:98–103.PubMedCrossRefGoogle Scholar
  30. 30.
    Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology. 1997;25:541–7.CrossRefGoogle Scholar
  31. 31.
    Radhakrishnan KR, Alkhouri N, Worley S, et al. Autoimmune hepatitis in children—impact of cirrhosis at presentation on natural history and long-term outcome. Dig Liver Dis. 2010;42:724–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardized SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259–64.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Ravi S, Shoreibah M, Raff E, et al. Autoimmune markers do not impact clinical presentation or natural history of steatohepatitis-related liver disease. Dig Dis Sci. 2015;60:3788–93.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Khairy M, El-Raziky M, El-Akel W, et al. Serum autoantibodies positivity prevalence in patients with chronic hepatitis C and impact on pegylated interferon and ribavirin treatment response. Liver Int. 2013;33:1504–9.PubMedGoogle Scholar
  35. 35.
    Bayraktar Y, Bayaktar M, Gurakar A, Hassanein TI, Van Thiel DH. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune disease. Hepato-Gastroenterology. 1997;44:417–25.PubMedGoogle Scholar
  36. 36.
    Bittencourt PL, Farias AQ, Porta G, Cancado EL, Miura I, Pugliese R, Kalil J, Goldberg AC, Carrilho FJ. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol. 2008;42(3):300–5.PubMedGoogle Scholar
  37. 37.
    Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–33.CrossRefGoogle Scholar
  38. 38.
    Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28:638–45.PubMedCrossRefGoogle Scholar
  39. 39.
    Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1:735–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002;35:890–7.CrossRefGoogle Scholar
  41. 41.
    Van Den Brand FF, Van der Veen KS, de Boer YS, et al. Increased mortality among patients with and without cirrhosis and autoimmune hepatitis. Clin Gastroenterol Hepatol. 2019;17:940–7.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Wen JW, Kohn MA, Wong R, et al. Hospitalizations for autoimmune hepatitis disproportionately affect Black and Latino Americans. Am J Gastroenterol. 2018;113(2):243–53.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Persaud A, Ahmed A, Kakked G, Shulik O, Ahlawat S. Association of Autoimmune Hepatitis and Cardiovascular Disease. Dig Liver Dis. 2019;51:1604–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Heneghan MA, Al-Chalabi T, McFarlane IG. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother. 2006;7:145–56.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Carolinas Medical Center-Atrium HealthCharlotteUSA

Personalised recommendations